James Hadfield

James Hadfield

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
RSRory Stark
Rory Stark
MGMarta Grzelak
Marta Grzelak
JHJames Hadfield
James Hadfield

7 April 2013 in Nature
Verified
Journal Article
Closed access
MMMuhammed Murtaza
Muhammed Murtaza
SDSarah-Jane Dawson
Sarah-Jane Dawson
DTDana W. Y. Tsui
Dana W. Y. Tsui
DGDavina Gale
Davina Gale
TFTim Forshew
Tim Forshew
NRNitzan Rosenfeld
Nitzan Rosenfeld

30 May 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TFTim Forshew
Tim Forshew
MMMuhammed Murtaza
Muhammed Murtaza
CPChristine Parkinson
Christine Parkinson
DGDavina Gale
Davina Gale
DTDana W. Y. Tsui
Dana W. Y. Tsui
NRNitzan Rosenfeld
Nitzan Rosenfeld
Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor mutations and tumor burden. Individual mutations have been probed using allele-specific assays, but sequencing of entire genes to detect cancer mutations in circulating DNA has not been demonstrated. We developed a method for tagged-amplicon deep sequencing (TAm-Seq) and screened 5995 genomic bases for low-frequency mutations. Using this method, we identified cancer mutations present in circulating DNA at allele frequencies as low as 2%, with sensitivity and specificity of >97%. We identified mutations throughout the tumor suppressor gene TP53 in circulating DNA from 46 plasma samples of advanced ovarian cancer patients. We demonstrated use of TAm-Seq to noninvasively identify the origin of metastatic relapse in a patient with multiple primary tumors. In another case, we identified in plasma an EGFR mutation not found in an initial ovarian biopsy. We further used TAm-Seq to monitor tumor dynamics, and tracked 10 concomitant mutations in plasma of a metastatic breast cancer patient over 16 months. This low-cost, high-throughput method could facilitate analysis of circulating DNA as a noninvasive “liquid biopsy” for personalized cancer genomics.

1 April 2010 in RNA
Verified
Journal Article
Closed access
PDF file
AGAnna Git
Anna Git
HDHeidi Dvinge
Heidi Dvinge
MSMali Salmon-Divon
Mali Salmon-Divon
MOMichelle Osborne
Michelle Osborne
CKClaudia Kutter
Claudia Kutter
CCCarlos Caldas
Carlos Caldas
RNA abundance and DNA copy number are routinely measured in high-throughput using microarray and next-generation sequencing (NGS) technologies, and the attributes of different platforms have been extensively analyzed. Recently, the application of both microarrays and NGS has expanded to include microRNAs (miRNAs), but the relative performance of these methods has not been rigorously characterized. We analyzed three biological samples across six miRNA microarray platforms and compared their hybridization performance. We examined the utility of these platforms, as well as NGS, for the detection of differentially expressed miRNAs. We then validated the results for 89 miRNAs by real-time RT-PCR and challenged the use of this assay as a “gold standard.” Finally, we implemented a novel method to evaluate false-positive and false-negative rates for all methods in the absence of a reference method.

20 May 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CMCharlie Massie
Charlie Massie
ALAndy Lynch
Andy Lynch
ARAntonio Ramos‐Montoya
Antonio Ramos‐Montoya
JBJoan Boren
Joan Boren
RSRory Stark
Rory Stark
IMIan G Mills
Ian G Mills
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 July 2009 in Methods
Verified
Journal Article
Closed access
DSDominic Schmidt
Dominic Schmidt
MWMichael D. Wilson
Michael D. Wilson
CSChristiana Spyrou
Christiana Spyrou
GBGordon D. Brown
Gordon D. Brown
JHJames Hadfield
James Hadfield
DODuncan T. Odom
Duncan T. Odom